Your Texas ASC billing company should deliver eight reports every month \u2014 and if it is delivering a collections summary instead, it is delivering history rather than intelligence, and your surgery center is making growth decisions on data that conceals which procedure categories are underperforming, which Texas payers are underpaying, and which denial categories are aging into permanent write-offs before your administrator identifies them.<\/p>\n
A monthly collections summary tells a Texas ASC CFO how much revenue arrived. The eight reports below tell a CFO whether the revenue that arrived represents what the facility was owed \u2014 and precisely where the difference went.<\/p>\n
Texas ASCs operate in a payer environment where BCBS of Texas, UnitedHealthcare, and Aetna each apply payer-specific ASC facility fee contract terms, multi-procedure discounting rules, and implant cost passthrough mechanisms that differ from their national policy frameworks. A billing company delivering a single collections figure against this payer complexity confirms revenue arrived without identifying whether it arrived correctly.<\/p>\n
For context on how Texas ASC billing complexity is evolving in 2026, see ASC Billing Challenges<\/a> 2025 and ASC Billing and Coding Guidelines<\/a>.<\/p>\n What it contains:<\/strong> NCR broken out by orthopedic, spine, ophthalmologic, pain management, and general surgery procedure categories \u2014 and by Texas payer: BCBS of Texas, UnitedHealthcare, Aetna, Humana, and Texas Medicaid managed care \u2014 with month-over-month trend lines and Texas ASC payer-specific benchmark comparisons for each cell.<\/p>\n Why it matters:<\/strong> a blended NCR of 93% across all procedure categories and all Texas payers conceals an 84% NCR on BCBS of Texas spine cases and a 97% NCR on UnitedHealthcare ophthalmologic cases \u2014 two completely different operational problems requiring two completely different corrective actions. The 84% BCBS of Texas spine NCR is driven by multi-procedure discounting logic that a billing company without Texas-specific payer contract knowledge applies incorrectly on every multi-level spine case. Identifying it requires a procedure-category and payer-separated NCR report.<\/p>\n Benchmark:<\/strong> 94% or above overall; 91%+ on Texas Medicare Advantage; 86%+ on Texas Medicaid managed care; procedure-specific benchmarks for orthopedic (93%+), spine (91%+), ophthalmologic (95%+), and pain management (90%+) against Texas payer-specific contracted rates.<\/p>\n What it contains:<\/strong> implant charges submitted versus expected implant charges per case \u2014 broken out by OR room, by procedure category (orthopedic hardware, spine instrumentation, ophthalmologic lenses, cardiac devices), and by surgeon \u2014 with month-over-month capture rate trend lines and variance from expected implant cost per case type.<\/p>\n Why it matters:<\/strong> a Texas ASC performing 150 orthopedic and spine cases monthly with a 12% implant capture failure rate loses $259,200 to $648,000 per 12 months in unbilled implant costs \u2014 a charge capture failure generating no denial and triggering no alert on a collections report. The only way to identify it is a report comparing actual implant charges submitted against expected implant charges per case type by OR room. When OR 3 shows a 15% implant capture variance and OR 1 shows 2%, the root cause is specific to OR 3’s charge capture workflow. For how implant revenue leakage compounds across ASC case volume, see ASC Implant Billing Revenue Leakage<\/a>.<\/p>\n Benchmark:<\/strong> 95% or above implant capture rate on every OR room for every procedure category; any OR room below 90% triggers an immediate charge capture workflow audit.<\/p>\n What it contains:<\/strong> all cases scheduled in the coming 30 days with authorization status \u2014 authorized, pending, not submitted, expired \u2014 broken out by procedure category and by Texas payer, with authorization validity window expiration dates and outstanding peer-to-peer review requests flagged by urgency.<\/p>\n Why it matters:<\/strong> a prior authorization status report is the only mechanism that surfaces authorization expiration risk before the case date \u2014 not after a denied claim lands in AR at 45 days. In Texas, where UnitedHealthcare and BCBS of Texas have expanded PA requirements on spine and orthopedic cases materially since 2022, a case scheduled without confirmed authorization represents $3,200 to $18,000 in facility fee revenue at risk of unauthorized-service denial. A PA status report gives the ASC administrator 30 days to correct authorization gaps before the case is performed. For how Texas payer-specific PA denial patterns are escalating in 2026, see Prior Auth Denial Trends 2026<\/a>.<\/p>\n Benchmark:<\/strong> 100% of scheduled cases in the coming 30 days with confirmed authorization status by the first business day of the month; zero cases with expired or unsubmitted authorization beyond day 10 of the month.<\/p>\n What it contains:<\/strong> all denials received in the prior month broken out by denial reason code (CO-4, CO-97, CO-167, PR-1, and others), procedure category, and Texas payer \u2014 with denial rate percentage by payer and procedure category, month-over-month trend lines, and corrective action status for each denial category exceeding the 8% threshold.<\/p>\n Why it matters:<\/strong> a blended denial rate of 7% across all Texas payers and procedure categories conceals a 14% denial rate on BCBS of Texas multi-procedure orthopedic cases (CO-97 bundling edit pattern) and a 3% denial rate on UnitedHealthcare ophthalmologic cases. Identifying the CO-97 bundling denial pattern on BCBS of Texas orthopedic cases requires a denial reason code and payer-separated report, not a blended denial count. For how denial patterns reveal billing company performance gaps, see Medical Billing Company Red Flags<\/a>.<\/p>\n Benchmark:<\/strong> below 5% overall first-pass denial rate; below 8% on any individual Texas payer; below 10% on any individual denial reason code category; any category exceeding benchmark receives a documented corrective action and 30-day resolution timeline in the report.<\/p>\n What it contains:<\/strong> contracted rate versus actual payment comparison by CPT code, revenue code, and Texas payer \u2014 broken out by procedure category \u2014 with variance amount per claim, aggregate variance by payer per month, and open dispute status on variances identified in prior months.<\/p>\n Why it matters:<\/strong> BCBS of Texas and UnitedHealthcare have documented patterns of applying internal payment edits that reduce facility fee payments on complex multi-procedure cases \u2014 spinal fusion with instrumentation, total joint replacement, multi-level pain management \u2014 below contracted allowables without generating a denial. A Texas ASC processing 200 surgical cases monthly with a 6% payer variance<\/strong> incidence rate and an average underpayment of $480 per case absorbs $691,200 per 12 months in silent underpayments that trigger no corrective action without a payer variance report running on every remittance cycle.<\/p>\n Benchmark:<\/strong> zero variance between contracted rate and actual payment on any Texas payer and procedure code combination; any variance above $50 per claim triggers a contracted-rate dispute filing within 15 business days of identification.<\/p>\n What it contains:<\/strong> AR aging broken out by 0\u201330, 31\u201360, 61\u201390, and 90-plus day buckets \u2014 separated by Texas payer, case type (orthopedic, spine, ophthalmologic, pain management), and failure mechanism (PA denial, bundling edit, implant passthrough, documentation correction, payer variance) \u2014 with active recovery work status on every claim in the 61-plus day bucket and filing window deadline dates on every claim in the 90-plus day bucket.<\/p>\n Why it matters:<\/strong> a blended AR aging report showing 18% of AR in the 90-plus day bucket does not tell a Texas ASC CFO whether that 18% is composed of recoverable implant passthrough claims with 30 days of filing window remaining, permanent write-off candidates where the window has closed, or PA expiration denials in the wrong appeal queue. An AR aging report segmented by failure mechanism converts a 90-day AR problem from a write-off event into a recovery workflow. For how 90-day AR misclassification drives permanent revenue loss, see Medical Billing Company Red Flags<\/a> and Revenue Cycle Management in Healthcare<\/a>.<\/p>\n Benchmark:<\/strong> below 15% of total AR in the 90-plus day bucket; 85% or more of the 90-plus day bucket actively worked in the trailing 30 days; zero claims in the 90-plus day bucket without a documented failure mechanism classification and recovery path assignment.<\/p>\n What it contains:<\/strong> all implant cost passthrough claims submitted in the prior month \u2014 broken out by Texas payer, by implant category (orthopedic hardware, spine instrumentation, ophthalmologic, cardiac), and by passthrough mechanism (separately payable HCPCS, invoice-based passthrough, cost-to-charge ratio) \u2014 with reconciliation of expected passthrough reimbursement against actual payment received and open dispute status on underpaid passthrough claims.<\/p>\n Why it matters:<\/strong> Texas payer-specific implant cost passthrough mechanisms differ materially by payer. BCBS of Texas applies a cost-to-charge ratio for implant reimbursement on certain procedure categories; UnitedHealthcare applies separately payable HCPCS thresholds; Aetna applies invoice-based passthrough with payer-specific markup limits. A billing company applying a uniform implant passthrough billing approach across all three Texas payers produces systematic underpayment on the payers whose mechanism differs from the approach applied.<\/p>\n Benchmark:<\/strong> 100% of implant cost passthrough claims reconciled against Texas payer-specific contracted passthrough mechanisms within 30 days of payment receipt; zero open underpaid passthrough claims older than 45 days without active dispute status.<\/p>\n What it contains:<\/strong> net realized revenue per OR room per month \u2014 calculated as gross facility fee revenue plus implant passthrough revenue minus contractual adjustments, payer variances, write-offs, and billing costs \u2014 broken out by procedure category and by Texas payer, with month-over-month trend lines and benchmark comparisons against Texas ASC payer-specific Yield EBITDA<\/strong> norms by procedure mix.<\/p>\n Why it matters:<\/strong> Yield EBITDA<\/strong> per OR is the single metric integrating all seven upstream reports into one bottom-line figure per revenue-generating asset. When OR 2 shows declining Yield EBITDA despite stable case volume, the root cause is upstream \u2014 implant capture failure, BCBS of Texas payer variance on spine cases, UnitedHealthcare PA denial escalation, or AR aging past the filing window \u2014 and all seven prior reports provide the diagnostic data to identify which upstream failure is driving the OR-level margin compression.<\/p>\n Benchmark:<\/strong> practice-specific, established at billing contract execution against Texas ASC payer-specific performance norms for the facility’s procedure mix, OR count, and geographic market \u2014 Houston, Dallas-Fort Worth, San Antonio, or Austin.<\/p>\n If your Texas ASC billing company cannot deliver all eight reports on the first business day of each month \u2014 populated with your facility’s actual claims data, segmented at the procedure-category and Texas-payer level, and benchmarked against Texas ASC payer-specific performance norms \u2014 it does not have the reporting infrastructure that ASC growth decisions require.<\/p>\n The corrective action is one of two paths: a reporting infrastructure improvement plan with a 90-day implementation timeline and documented deliverable specifications \u2014 or a billing company transition to MBC’s ASC billing infrastructure, which delivers all eight reports as standard monthly deliverables before the next billing cycle opens.<\/p>\n MBC’s ASC Billing Services<\/strong><\/a> delivers all eight reports as standard monthly deliverables \u2014 not request-based exports or quarterly reviews. Our dedicated account manager<\/strong> populates every report with your Texas ASC’s actual claims data, benchmarks every metric against Texas payer-specific ASC performance norms, flags every metric below benchmark with the specific denial root-cause<\/strong> or billing failure mechanism driving it, and presents every corrective action with a 30-day resolution timeline before the next billing cycle opens.<\/p>\n With MBC’s 97% clean claim rate<\/strong> and proven 30% A\/R reduction within 90 days<\/strong>, Texas ASCs receiving all eight reports monthly recover an average of $420,000 to $1,800,000 per 12 months in revenue their previous billing vendor was systematically missing across implant capture, payer variance, and Old AR Recovery<\/strong><\/a> categories. For Texas-specific ASC billing context, see Texas Medical Billing Services<\/a> and ASC Billing and Coding Guidelines<\/a>.<\/p>\n Practices completing MBC’s Complimentary 90-Day AR Diagnostic<\/strong><\/a> receive all eight reports populated with their actual Texas ASC claims data \u2014 with gap analysis, Texas payer-specific benchmarks, and a 90-day correction roadmap before the next billing cycle closes.<\/p>\n Request Your Free Revenue Diagnostic<\/strong><\/a> \u2014 contact us at info@medicalbillersandcoders.com<\/a> or call 888-357-3226<\/strong>.<\/p>\n Medical Billing Services<\/a> | medicalbillersandcoders.com | 888-357-3226<\/em><\/p>\n Q1. Why is a monthly collections summary insufficient for a Texas ASC to evaluate billing company performance?<\/strong> Q2. How often should a Texas ASC review its prior authorization status report?<\/strong> Q3. What is the difference between a denial summary report and a payer variance report for a Texas ASC?<\/strong> Q4. What does Yield EBITDA per OR reveal that a standard NCR report does not?<\/strong> Q5. What should a Texas ASC administrator do if the billing company cannot produce all eight reports within five business days of request?<\/strong> Your Texas ASC billing company should deliver eight reports every month \u2014 and if it is delivering a collections summary instead, it is delivering history rather than intelligence, and your surgery center is making growth decisions on data that conceals which procedure categories are underperforming, which Texas payers are underpaying, and which denial categories are […]<\/p>\n","protected":false},"author":1,"featured_media":31099,"menu_order":0,"template":"","meta":{"footnotes":""},"wpseo_locations_category":[5956],"class_list":["post-31083","wpseo_locations","type-wpseo_locations","status-publish","has-post-thumbnail","hentry","wpseo_locations_category-anesthesia-billing-services-in-new-york"],"yoast_head":"\n
\nReport 1 \u2014 Net Collection Rate by Procedure Category and by Texas Payer<\/h3>\n
\nReport 2 \u2014 Implant Revenue Capture Rate by OR and by Procedure Category<\/h3>\n
\nReport 3 \u2014 Prior Authorization Status Report by Case Type and by Texas Payer<\/h3>\n
\nReport 4 \u2014 Denial Summary by Denial Reason Code, Procedure Category, and Texas Payer<\/h3>\n
\nReport 5 \u2014 Payer Variance Report by Texas Payer and Revenue Code<\/h3>\n
\nReport 6 \u2014 AR Aging Report by Payer, Case Type, and Failure Mechanism<\/h3>\n
\nReport 7 \u2014 Implant Cost Passthrough Reconciliation Report<\/h3>\n
\nReport 8 \u2014 Yield EBITDA per OR per Month<\/h3>\n
\nWhat to Do If Your Texas ASC Billing Company Cannot Deliver These Eight Reports<\/h3>\n
\nHow MBC Delivers These Eight Reports for Texas ASCs<\/h3>\n
\nFrequently Asked Questions<\/h3>\n
\nA monthly collections summary reports aggregate revenue received without identifying whether the revenue received matches contracted allowables, whether implant charges were fully captured at case completion, whether prior authorization denials are being correctly triaged by failure mechanism, or whether payer variance events are reducing facility fee payments below contracted rates. For a Texas ASC operating in a multi-payer environment with BCBS of Texas, UnitedHealthcare, and Aetna each applying distinct contract terms, a collections summary conceals all of these revenue gaps behind a single number that confirms revenue arrived without confirming it arrived correctly.<\/p>\n
\nThe prior authorization status report should be reviewed on the first business day of each month for all cases scheduled in the coming 30 days \u2014 and re-reviewed weekly for cases scheduled in the coming 14 days with authorization still in pending status. Texas Medicare Advantage plans<\/a> apply authorization validity windows as short as 30 days, meaning an authorization obtained in month one for a case rescheduled to month two may have expired \u2014 requiring re-authorization before the case date or generating an unauthorized-service denial on a $3,200 to $18,000 facility fee case.<\/p>\n
\nA denial summary report identifies claims formally rejected by Texas payers with a denial reason code \u2014 CO-4, CO-97, CO-167, and others \u2014 that require an appeal or corrected resubmission. A payer variance report identifies claims paid by Texas payers at amounts below the contracted allowable without a denial being generated \u2014 a silent underpayment event that requires a contracted-rate dispute filing rather than a denial appeal. Both reports are required monthly because the two failure categories have different financial impacts, different correction processes, and different filing window deadlines.<\/p>\n
\nNCR measures the percentage of collectible revenue that was collected \u2014 it does not account for billing costs, write-offs, payer variance adjustments, or implant passthrough reconciliation losses. Yield EBITDA<\/strong> per OR integrates all of these components into a single net realized revenue figure per revenue-generating asset \u2014 revealing whether OR 2 is producing lower net revenue than OR 1 despite similar case volumes, and surfacing the upstream billing failure driving the per-OR margin gap that an NCR report averages across all ORs.<\/p>\n
\nA Texas ASC billing company that cannot produce all eight reports within five business days of request is disclosing, through its inability to report, the same operational gaps the reports would reveal if the data were available. The immediate corrective action is a formal reporting infrastructure audit: requesting documentation of the billing company’s reporting system architecture, data extraction methodology, and benchmark source for each of the eight report types. If the billing company cannot produce this documentation within 10 business days, the contract renewal conversation should begin \u2014 with MBC’s pre-transition AR protection protocol ensuring no Texas payer filing window closes during the changeover.<\/p>\nASC Billing Services in Texas<\/span><\/h3>